Abstract:Immune checkpoint inhibitors have garnered significant attention in oncological research over recent years. A plethora of studies have elucidated that inhibitors targeting the Programmed Death-Ligand 1 (PD-L1) play a pivotal role in circumventing the evasion mechanisms of cancer cells against the immune system. This study aimed to develop an integrated screening model combining an Artificial Neural Network (ANN), Molecular Similarity (MS) assessments, and GNINA 1.0 molecular docking, targeting PD-L1 inhibitors. A database of 2044 substances with known PD-L1 inhibitory activity was compiled from Google Patents and used to enhance molecular similarity evaluations and train the machine learning model. For retrospective validation of the docking procedure, the human PD-L1 protein, with the Protein Data Bank (PDB) ID: 5N2F, was employed as a control. In this phase of the study, 15,235 compounds from the DrugBank database were subjected to a series of screening processes: initially through medicinal chemistry filters, followed by MS assessments, the ANN model, and culminating with molecular docking using GNINA 1.0. The decoy generation yielded promising outcomes, evidenced by an AUC-ROC 1NN value of 0.52 and Doppelganger scores with a mean of 0.24 and a maximum of 0.346, indicating a high resemblance of the decoys to the active set. For MS, the AVALON emerged as the most effective fingerprint for similarity searching, demonstrating an Enrichment Factor (EF) of 1% at 10.96%, an AUC-ROC of 0.963, and an optimal similarity threshold of 0.32. The ANN model demonstrated superior performance in cross-validation, achieving an average precision of 0.863±0.032 and an F1 score of 0.745±0.039, outperforming both the Support Vector Classifier (SVC) and Random Forest (RF) models, albeit not significantly. In external validation, the ANN model maintained its superiority with an average precision of 0.851 and an F1 score of 0.790. GNINA 1.0, employed for molecular docking, was validated through redocking and retrospective control, achieving an AUC of 0.975, with a critical cnn_pose_score threshold of 0.73. From the initial 15,235 compounds, 128 were shortlisted using the MS and ANN models. Further screening through GNINA 1.0 identified 22 potential candidates, among which (3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid emerged as the most promising, with a cnn_pose_score of 0.79, a PD-L1 inhibitory probability of 70.5%, and a Tanimoto coefficient of 0.35.

Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction

Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors

Innovative Virtual Screening of PD-L1 Inhibitors: The Synergy of Molecular Similarity, Neural Networks, and GNINA Docking

Towards novel small-molecule inhibitors blocking PD-1/PD-L1 pathway: From explainable machine learning models to molecular dynamics simulation

Data-augmented machine learning scoring functions for virtual screening of YTHDF1 m6A reader protein

In silico exploration of PD-L1 binding compounds: Structure-based virtual screening, molecular docking, and MD simulation

PDL1Binder: Identifying Programmed Cell Death Ligand 1 Binding Peptides by Incorporating Next-Generation Phage Display Data and Different Peptide Descriptors.

Partial Least-Squares Discriminant Analysis and Ensemble-Based Flexible Docking of PD-1/PD-L1 Inhibitors: A Pilot Study.

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Identification of Novel PD-1/PD-L1 Small Molecule Inhibitors: Virtual Screening, Synthesis and in Vitro Characterisation

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products

Deep Learning-Driven Discovery of FDA-Approved BCL2 Inhibitors: In Silico Analysis Using a Deep Generative Model NeuralPlexer for Drug Repurposing in Cancer Treatment

In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models

Computational Insight into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship.

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Molecular modeling studies of Indoline Scaffold derivatives as PD‐1/PD‐L1 pathway inhibitors by QSAR, molecular docking and molecular dynamics simulation techniques

Integrated Molecular Modeling and Machine Learning for Drug Design

Pd-1-Targeted Discovery Of Peptide Inhibitors By Virtual Screening, Molecular Dynamics Simulation, And Surface Plasmon Resonance